Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says
Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020.
Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber Cancer Institute have released some much-needed good news. In their study, published in the journal Frontiers of Oncology on July 23, the researchers revealed that a chemical found in cannabis has demonstrated “significant therapy potential” in treatment of pancreatic cancer.
Stories you may be interested in
Finally, Georgia can grow medical marijuana. Here’s what you need to know.
Four years ago, Governor Nathan Deal signed into law Haleigh’s Hope Act, which made low-THC cannabis oil legal to use by those with certain medical conditions. However, as it was still against the law to buy or grow marijuana in the state, it was virtually impossible to obtain the oil in Georgia. Patients were forced…
Read More Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More After marijuana edibles helped dying Holocaust survivor battle Alzheimer’s, his family’s foundation pushes for more research
A Massachusetts family’s experience giving marijuana edibles to their dying patriarch is set to kick off a desperately needed investigation into how cannabis might treat some of the more troubling symptoms of Alzheimer’s disease, a condition that affects 5.7 million Americans. Read the full story here.
Read More New Feature: Calendar Integration
At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More An Alternative Treatment for Parkinson’s Patients
April is Parkinson’s Awareness Month and an opportune time to highlight the disease and how medical marijuana may be a beneficial treatment option for those living with the condition. Many Parkinson’s patients find themselves desperate for alternative treatment options that provide sufficient relief of their symptoms and help avoid or postpone the need for surgery…
Read More Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools
A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More